RT Journal Article
T1 Latanoprost/timolol fixed-dose combination: two decades of efficacy and safety in glaucoma management
A1 Martínez De La Casa Fernández-Borrella, José María
A1 Fernández Vila, Pedro Corsino
A1 Grzybowski, Andrzej
A1 Tatham, Andrew
A1 Vignesh, Shivani Ohri
A1 Hassan, Tarek
AB Topical prostaglandin analogs (PGAs) are recommended as first-line therapy for the treatment of glaucoma. However, many patients do not achieve adequate IOP control with monotherapy and require additional agents. Combination therapy involving the use of two individual eye drops makes the medication instillation regimen complex, often leading to reduced adherence to treatment. Lack of adherence leads to poor outcomes. Fixed combinations of glaucoma pharmacotherapies can simplify the dosing regimen, increase adherence, and improve the quality of life (QoL). Latanoprost 0.005% and timolol maleate 0.5% fixed combination (LTFC) was the first PGA/βeta-blocker (BB) combination, launched in the European Union in 2001, and continues to be widely used. Studies have reported improved QoL and patient satisfaction with LTFC compared to monotherapy or other combination therapies. A high level of satisfaction with LTFC concerning tolerability and good adherence has also been reported. In several studies comparing LTFC with other monotherapies, LTFC consistently showed a higher reduction in intraocular pressure (IOP). Some studies have also shown that LTFC leads to a greater reduction in IOP than other combination therapies. Thus, LTFC can be useful in the management of patients with inadequate IOP control on monotherapy.
PB Springer
YR 2026
FD 2026-01
LK https://hdl.handle.net/20.500.14352/131025
UL https://hdl.handle.net/20.500.14352/131025
LA eng
NO Martinez-de-la-Casa, J., Corsino, P., Grzybowski, A. et al. Latanoprost/timolol fixed-dose combination: two decades of efficacy and safety in glaucoma management. BMC Ophthalmol 26, 14 (2026). https://doi.org/10.1186/s12886-025-04568-w
NO Viatris
DS Docta Complutense
RD 13 abr 2026